The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in patients with mCRC that progressed on prior oxaliplatin treatment.
Paul Ruff
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Amgen; Sanofi
Other Remuneration - Amgen
Radek Lakomy
Research Funding - Sanofi
Jana Prausová
No relevant relationships to disclose
Guy Van Hazel
No relevant relationships to disclose
Vladimir Mikhailovich Moiseyenko
No relevant relationships to disclose
Pankaj Bhargava
Employment or Leadership Position - Sanofi
Josep Tabernero
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Genentech; Merck KGaA; Millennium; Novartis; Onyx
Honoraria - Amgen; Merck KGaA; Novo Nordisk; Roche; Sanofi
Eric Van Cutsem
Research Funding - Sanofi